Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn

The protein tyrosine kinase Pyk2 is encoded by PTK2B, a novel Alzheimer’s disease (AD) susceptibility variant, with the PTK2B risk allele being associated with increased mRNA levels, suggestive of increased Pyk2 levels. However, the role of Pyk2, a member of the focal adhesion kinase (FAK) family, in AD pathology and its regulation are largely unknown. To address this, we generated mice with neuronal expression of human Pyk2. Because we had previously reported an association of Pyk2 and hyperphosphorylated tau (a hallmark feature of AD) in human tau transgenic pR5 mice, we also generated Pyk2/tau double-transgenic mice, which exhibit increased tyrosine phosphorylation and accumulation of tau. We further demonstrated that Pyk2 colocalizes, interacts with, and phosphorylates tau in vivo and in vitro. Importantly, although Pyk2 interacts with the established tyrosine-directed tau kinase Fyn, we identified an increased Pyk2 activity in mice which constitutively overexpress Fyn (FynCA), and a decreased activity in mice lacking Fyn (FynKO). Together, our study reveals a novel role for Pyk2 as a direct tyrosine kinase of tau that is active downstream of Fyn. Our analysis may enhance the understanding of how the PTK2B risk allele contributes to tauopathy.

[1]  J. Götz,et al.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn‐mediated local protein translation , 2017, The EMBO journal.

[2]  J. Götz,et al.  Tau-based therapies in neurodegeneration: opportunities and challenges , 2017, Nature Reviews Drug Discovery.

[3]  J. Girault,et al.  Pyk2 modulates hippocampal excitatory synapses and contributes to cognitive deficits in a Huntington's disease model , 2017, Nature Communications.

[4]  K. Vossel,et al.  Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture , 2017, Molecular Neurodegeneration.

[5]  D. Holtzman,et al.  Elucidating the Role of TREM2 in Alzheimer’s Disease , 2017, Neuron.

[6]  Wendy Noble,et al.  Roles of tau protein in health and disease , 2017, Acta Neuropathologica.

[7]  B. Hyman,et al.  Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease , 2017, Synapse.

[8]  D. Xia,et al.  Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment , 2017, Acta Neuropathologica.

[9]  P. Reddy,et al.  Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. , 2016, Human molecular genetics.

[10]  H. Soininen,et al.  Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology , 2016, Molecular Psychiatry.

[11]  K. Vuori,et al.  Novel Role of Src in Priming Pyk2 Phosphorylation , 2016, PloS one.

[12]  R. Brandt,et al.  Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease , 2016, Drugs.

[13]  L. Buée,et al.  Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo , 2015, Neurobiology of Disease.

[14]  M. Falasca,et al.  The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets. , 2015, The Biochemical journal.

[15]  D. Xia,et al.  Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. , 2015, Biochimica et biophysica acta.

[16]  Matthew Schreiber,et al.  Alzheimer’s Disease Genetics , 2014, Current Behavioral Neuroscience Reports.

[17]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[18]  Manolis Kellis,et al.  Alzheimery's disease pathology is associated with early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci , 2014, Nature Neuroscience.

[19]  D. Xia,et al.  Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn , 2014, Front. Mol. Neurosci..

[20]  M. Hemberg,et al.  Tau promotes neurodegeneration through global chromatin relaxation , 2014, Nature Neuroscience.

[21]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[22]  J. Götz,et al.  Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice , 2013, Neurobiology of Aging.

[23]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[24]  D. Bennett,et al.  The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease , 2012, The Journal of Neuroscience.

[25]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[26]  S. Andrews,et al.  Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a “P301L” tau knockin mouse , 2012, Neurobiology of Aging.

[27]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[28]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[29]  M. Sheng,et al.  Proline-Rich Tyrosine Kinase 2 Regulates Hippocampal Long-Term Depression , 2010, The Journal of Neuroscience.

[30]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[31]  R. Salgia,et al.  Fyn: a novel molecular target in cancer. , 2010, Cancer.

[32]  J. Hell,et al.  Postsynaptic Clustering and Activation of Pyk2 by PSD-95 , 2010, The Journal of Neuroscience.

[33]  C. Lipinski,et al.  Targeting Pyk2 for therapeutic intervention , 2010, Expert opinion on therapeutic targets.

[34]  J. Götz,et al.  Divergent phosphorylation pattern of tau in P301L tau transgenic mice , 2008, The European journal of neuroscience.

[35]  R. Geahlen,et al.  The microtubule-associated protein tau is phosphorylated by Syk , 2008, Biochimica et biophysica acta.

[36]  Jürgen Götz,et al.  Pronuclear injection for the production of transgenic mice , 2007, Nature Protocols.

[37]  K. Ashe,et al.  Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy , 2007, The Journal of Neuroscience.

[38]  S. Yen,et al.  Disease-related Modifications in Tau Affect the Interaction between Fyn and Tau* , 2005, Journal of Biological Chemistry.

[39]  Wendy Noble,et al.  Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase , 2005, The Journal of Neuroscience.

[40]  Feng Chen,et al.  Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals. , 2004, Current drug targets.

[41]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[42]  G. Rodan,et al.  PYK2 Autophosphorylation, but Not Kinase Activity, Is Necessary for Adhesion-induced Association with c-Src, Osteoclast Spreading, and Bone Resorption* , 2003, The Journal of Biological Chemistry.

[43]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[44]  J. Roder,et al.  CAKβ/Pyk2 Kinase Is a Signaling Link for Induction of Long-Term Potentiation in CA1 Hippocampus , 2001, Neuron.

[45]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[46]  S. Lev,et al.  A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation , 1996, Nature.

[47]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Keith A. Johnson,et al.  Modulation of TREM2 by CD33: a protein QTL study integrates Alzheimer loci in human monocytes , 2016 .

[49]  G. Eckert,et al.  Mitochondrial dysfunction: cause and consequence of Alzheimer's disease. , 2014, Progress in molecular biology and translational science.

[50]  R. Salgia,et al.  Fyn , 2010, Cancer.